Aclaris Therapeutics, Inc.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $7.8M
- Net income
- -$64.9M
- Total assets
- $160.5M
- Market cap
- $608.9M
- Gross margin
- 73.3%
- Operating margin
- -975.9%
- Net margin
- -829.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $7.8M
- Cost of revenue
- $2.1M
- Gross profit
- $5.7M
- Operating expenses
- $82.1M
- Operating income
- -$76.4M
- Net income
- -$64.9M
- EPS (basic)
- $-0.53
- EPS (diluted)
- $-0.53
Balance sheet
- Total assets
- $160.5M
- Current assets
- $96.3M
- Total liabilities
- $57.4M
- Current liabilities
- $28.6M
- Shareholders’ equity
- $103.1M
Cash flow
- Operating cash flow
- -$47.1M
- Investing cash flow
- $48.4M
- Financing cash flow
- -$5.9M
- Net cash flow
- -$4.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $608.9M
- EPS (diluted)
- $-0.53
- Shares outstanding
- 139.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 7, 2015
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $64.9M in FY2025.
- Revenue grew 16% from FY2021 to FY2025.
- Gross margin of 73.3%, net margin -829.6%.
- Trading 14% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Aclaris Therapeutics, Inc..
Write a review
News about Aclaris Therapeutics, Inc.
News & sentiment via Polygon.io
